Literature DB >> 28625373

High-risk echocardiographic features predict mortality in pulmonary arterial hypertension.

Christopher Austin1, Charles Burger2, Garvan Kane3, Robert Safford1, Joseph Blackshear1, Ryan Ung1, Jordan Ray1, Ali Alsaad4, Khadija Alassas1, Brian Shapiro5.   

Abstract

AIMS: Echocardiography is the most common imaging modality for assessment of the right ventricle in patients with pulmonary arterial hypertension (PAH). Echocardiographic parameters were identified as independent risk factors for mortality in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) and other PAH cohorts. We sought to identify readily obtained echocardiographic features associated with PAH survival. METHODS AND
RESULTS: Retrospective analysis of 175 patients with Group 1 was performed. Baseline clinical and laboratory assessment including REVEAL risk criteria were obtained and standard 2-Dimensional and Doppler echocardiography performed at baseline was reviewed. Univariate and multivariate analyses of echocardiographic parameters were performed. Estimated right atrial pressure> 15 mmHg (HR 2.39, P = .02), tricuspid regurgitation ≥ moderate (HR 2.16, P = .04), and presence of pericardial effusion (HR 1.8, P = .05) were identified as independent, high-risk echocardiographic features in PAH. A validation cohort of 677 patients was identified and Kaplan-Meier survival analysis was performed in both cohorts. High-risk echocardiographic features stratified survival curves of both cohorts (P < .01 for all). The presence of 3 high-risk echocardiographic features greatly increased risk of 1-year (RR 4.86) and 3-year (RR 3.35) mortality (P < .05 for both).
CONCLUSION: Estimated right atrial pressure> 15, tricuspid regurgitation ≥ moderate, and presence of pericardial effusion are high-risk echocardiographic features in PAH. When seen in combination, these features greatly increase risk of mortality in PAH and may lead to more timely enhanced therapy for patients identified as having an increased risk for death.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28625373     DOI: 10.1016/j.ahj.2017.04.013

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.

Authors:  Manreet Kanwar; Amresh Raina; Lisa Lohmueller; Jidapa Kraisangka; Raymond Benza
Journal:  Curr Hypertens Rep       Date:  2019-04-25       Impact factor: 5.369

2.  Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.

Authors:  Sophia Emmons-Bell; Catherine Johnson; Alexandra Boon-Dooley; Paul A Corris; Peter J Leary; Stuart Rich; Magdi Yacoub; Gregory A Roth
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

3.  The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.

Authors:  Emma Derrett-Smith; Kristina E N Clark; Xu Shiwen; David J Abraham; Rachel K Hoyles; Olivier Lacombe; Pierre Broqua; Jean Louis Junien; Irena Konstantinova; Voon H Ong; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2021-09-06       Impact factor: 5.156

4.  Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension.

Authors:  Scott A Helgeson; J Saadi Imam; John E Moss; David O Hodge; Charles D Burger
Journal:  Diseases       Date:  2018-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.